MiR-143 targets CTGF and exerts tumor-suppressing functions in epithelial ovarian cancer

American Journal of Translational Research

Volumn 8, Issue 6, 2016, Pages 2716-2726

  Wang, Lufei ^a   He, Jin ^b   Xu, Hongmei ^b   Xu, Longjie ^b   Li, N ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

CTGF; Epithelial ovarian carcinoma; Micrornas; MiR 143

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; SMALL INTERFERING RNA;

ADULT; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE GROWTH FACTOR GENE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MIDDLE AGED; OVARY CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84976423784     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Permuth-Wey J and Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol 2009; 472: 413-437.
3. Bristow RE. Surgical standards in the management of ovarian cancer. Curr Opin Oncol 2000; 12: 474-480.
4. Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, Kommoss S, Heitz F, Traut A and du Bois A. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 2011; 121: 615-619.
5. Harries M and Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 2002; 3: 537-545.
6. Osada H and Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007; 28: 2-12.
7. Tie J, Fan D. Big roles of microRNAs in tumorigenesis and tumor development. Histol Histopathol 2011; 26: 1353-1361.
8. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
9. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 2005; 4: 1179-1184.
10. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103: 2257-2261.
11. Kinose Y, Sawada K, Nakamura K and Kimura T. The role of microRNAs in ovarian cancer. Biomed Res Int 2014; 2014: 249393.
12. Wang Y, Kim S and Kim IM. Regulation of Metastasis by microRNAs in Ovarian Cancer. Front Oncol 2014; 4: 143.
13. Su J, Liang H, Yao W, Wang N, Zhang S, Yan X, Feng H, Pang W, Wang Y, Wang X, Fu Z, Liu Y, Zhao C, Zhang J, Zhang CY, Zen K, Chen X and Wang Y. MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS One 2014; 9: e114420.
14. Hirahata M, Osaki M, Kanda Y, Sugimoto Y, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Kawai A, Ito H, Ochiya T and Okada F. PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma. Cancer Med 2016;
15. Liu J, Mao Y, Zhang D, Hao S, Zhang Z, Li Z and Li B. MiR-143 inhibits tumor cell proliferation and invasion by targeting STAT3 in esophageal squamous cell carcinoma. Cancer Lett 2016; 373: 97-108.
16. Zhai L, Ma C, Li W, Yang S and Liu Z. miR-143 suppresses epithelial-mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5. Mol Carcinog 2015; [Epub ahead of print].
17. Wei J, Ma Z, Li Y, Zhao B, Wang D, Jin Y and Jin Y. miR-143 inhibits cell proliferation by targeting autophagy-related 2B in non-small cell lung cancer H1299 cells. Mol Med Rep 2015; 11: 571-576.
18. Wang L, Shi ZM, Jiang CF, Liu X, Chen QD, Qian X, Li DM, Ge X, Wang XF, Liu LZ, You YP, Liu N and Jiang BH. MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget 2014; 5: 5416-5427.
19. Yang MH, Lin BR, Chang CH, Chen ST, Lin SK, Kuo MY, Jeng YM, Kuo ML and Chang CC. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene 2012; 31: 2401-2411.
20. Mao Y, Liu J, Zhang D and Li B. miR-143 inhibits tumor progression by targeting FAM83F in esophageal squamous cell carcinoma. Tumour Biol 2016;
21. Wang L, Shi ZM, Jiang CF, Liu X, Chen QD, Qian X, Li DM, Ge X, Wang XF, Liu LZ, You YP, Liu N and Jiang BH. MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget 2014; 5: 5416-5427.
22. Zhou P, Chen WG and Li XW. MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer. Am J Cancer Res 2015; 5: 2056-2063.
23. Zhai L, Ma C, Li W, Yang S and Liu Z. miR-143 suppresses epithelial-mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5. Mol Carcinog 2015.
24. Abreu JG, Ketpura NI, Reversade B and De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002; 4: 599-604.
25. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62-64.
26. Leask A and Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006; 119: 4803-4810.
27. Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M, Ogawa A and Sawai T. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma. Neurol Res 2002; 24: 677-683.
28. Lacle MM, van Diest PJ, Goldschmeding R, van der Wall E and Nguyen TQ. Expression of connective tissue growth factor in male breast cancer: clinicopathologic correlations and prognostic value. PLoS One 2015; 10: e0118957.
29. Lamarca A, Mendiola M, Bernal E, Heredia V, Diaz E, Miguel M, Pastrian LG, Burgos E, Feliu J and Barriuso J. Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC). Curr Cancer Drug Targets 2015; 15: 435-444.
30. Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, Li B, Tong XJ and Xie D. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem 2007; 282: 36571-36581.
31. Kwon S, Munroe X, Crawley SC, Lee HY, Spong S, Bradham D, Gum JR Jr, Sleisenger MH and Kim YS. Expression of connective tissue growth factor in pancreatic cancer cell lines. Int J Oncol 2007; 31: 693-703.
32. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD and Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005; 65: 8887-8895.
33. Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW and Koeffler HP. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005; 11: 7243-7254.
34. Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ and Samimi G. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget 2015; 6: 44551-62.